Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease

Chrishan S Samuel, Hasangika Bodaragama, Jackie Chew, Robert E Widdop, Simon G Royce, Tim D Hewitson

Research output: Contribution to journalArticleResearchpeer-review

50 Citations (Scopus)

Abstract

Relaxin is a naturally occurring peptide hormone that mediates systemic hemodynamic and renal adaptive changes during pregnancy and abrogates aberrant scar tissue formation (fibrosis) in diverse pathogeneses. However, its efficacy relative to renin-angiotensin system blockade, the most effective antifibrotic strategy currently available, is not known. We compared the individual versus combined antifibrotic effects of serelaxin (a recombinant form of human gene-2 relaxin) and the angiotensin-converting enzyme inhibitor enalapril, in preventative (started before injury) and therapeutic (treatment of established fibrosis) strategies, in a mouse model of isoprenaline-induced cardiac injury (at 17 days). Changes in systolic blood pressure, organ hypertrophy, and tissue remodeling/fibrosis were assessed. Pretreatment with serelaxin (0.5 mg/kg per day via subcutaneous administration) alone reduced cardiac fibrosis to a greater extent than enalapril (200 mg/L via drinking water; equivalent to 48 mg/kg per day) alone (P
Original languageEnglish
Pages (from-to)315 - 322
Number of pages8
JournalHypertension
Volume64
Issue number2
DOIs
Publication statusPublished - 2014

Cite this